In a recent filing with the Securities and Exchange Commission, Bailey Gregory, a director at Serina Therapeutics, Inc. (NASDAQ:SER), reported a purchase of 3,866 shares of the company's common stock. The shares were acquired on December 17, 2024, at a weighted average price of $4.5899 per share, amounting to a total transaction value of approximately $17,744. This acquisition increased Gregory's direct ownership to 67,243 shares. The purchase price ranged from $4.54 to $4.74 per share. The timing of this insider purchase is notable, as InvestingPro data shows the stock has gained over 30% in the past week, though it remains down 47% over the last six months. With a current market cap of $52 million and an overall weak financial health score according to InvestingPro, investors seeking deeper insights can access 8 additional ProTips and comprehensive analysis through an InvestingPro subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.